{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:59:09Z","timestamp":1780822749748,"version":"3.54.1"},"reference-count":124,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ard.2025.11.024","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:37:00Z","timestamp":1767011820000},"page":"588-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-9934","authenticated-orcid":false,"given":"Iftach","family":"Sagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R W","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rdc.2010.05.004","article-title":"The history of ANCA-associated vasculitis","volume":"36","author":"Ball","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0003","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.41983","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification criteria for microscopic polyangiitis","volume":"74","author":"Suppiah","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.41986","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification criteria for granulomatosis with polyangiitis","volume":"74","author":"Robson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2025.11.024_bib0007","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1016\/S2665-9913(24)00187-5","article-title":"Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort","volume":"6","author":"Gisslander","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0008","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.11.024_bib0009","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitis update: genetic pathogenesis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0010","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41584-022-00819-y","article-title":"Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management","volume":"18","author":"Trivioli","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0012","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1681\/ASN.2010090928","article-title":"Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease","volume":"22","author":"Olson","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.024_bib0013","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/annrheumdis-2012-202986","article-title":"Regulatory B cells in ANCA-associated vasculitis","volume":"72","author":"Wilde","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2025.11.024_bib0014","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1681\/ASN.2013060606","article-title":"Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis","volume":"25","author":"Nakazawa","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0016","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.ajkd.2005.01.001","article-title":"Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs","volume":"45","author":"Schlieben","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ard.2025.11.024_bib0017","article-title":"Immune cell crosstalk between ANCA-associated vasculitis and IgG4-related disease: an unresolved pathogenic link","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/antib12010025","article-title":"New insights into pathogenesis and treatment of ANCA-associated vasculitis: autoantibodies and beyond","volume":"12","author":"Paroli","year":"2023","journal-title":"Antibodies (Basel)"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0019","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1681\/ASN.2006020108","article-title":"Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis","volume":"17","author":"Ruth","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.11.024_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1156212","article-title":"Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future","volume":"14","author":"Pan","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.ard.2025.11.024_bib0023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005323","article-title":"Decreased concentrations of C5a complement receptor antibodies are associated with relapse in eosinophilic granulomatosis with polyangiitis (EGPA)","volume":"11","author":"Klapa","year":"2025","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40620-022-01414-w","article-title":"Comparative analysis of complement C3 and C4 serum levels for outcome prediction in ANCA-associated renal vasculitis","volume":"36","author":"Tampe","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.ard.2025.11.024_bib0026","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.ard.2025.11.024_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2018.09.037","article-title":"Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis","volume":"108","author":"Mo","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0028","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/cea.13209","article-title":"Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis","volume":"48","author":"Tsurikisawa","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0029","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/biomedicines11030776","article-title":"EGPA Phenotyping: not only ANCA, but also eosinophils","volume":"11","author":"Matucci","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ard.2025.11.024_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251318615","article-title":"Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Hua","year":"2025","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0031","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"10427","key":"10.1016\/j.ard.2025.11.024_bib0032","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.11.024_bib0034","series-title":"Firestein & Kelley\u2019s Textbook of Rheumatology","first-page":"1616","article-title":"Anti-neutrophil cytoplasmic antibody-associated vasculitis","author":"Paul","year":"2024"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0950-3579(97)80052-0","article-title":"Disease assessment and management of the vasculitides","volume":"11","author":"Luqmani","year":"1997","journal-title":"Baillieres Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0036","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ard.2025.11.024_bib0037","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0038","first-page":"31","article-title":"Development and validation of a disease extent index for Wegener\u2019s granulomatosis","volume":"55","author":"de Groot","year":"2001","journal-title":"Clin Nephrol"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0039","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0041","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/ard.2009.122952","article-title":"Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index","volume":"70","author":"Suppiah","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.11.024_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0043","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.ard.2025.11.024_bib0044","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1093\/rheumatology\/keac175","article-title":"Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review","volume":"61","author":"Berti","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2025.11.024_bib0045","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s10067-022-06267-z","article-title":"BVAS version 3 and BVAS\/GPA: standing on the same line?","volume":"41","author":"Ahn","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0046","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2012-202111","article-title":"Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)","volume":"72","author":"Dolezalova","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0047","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.090387","article-title":"Predictors of damage and survival in patients with Wegener\u2019s granulomatosis: analysis of 50 patients","volume":"37","author":"Kamali","year":"2010","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0048","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0049","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1681\/ASN.0000000000000274","article-title":"The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials","volume":"35","author":"Bate","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.024_bib0050","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","article-title":"Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire","volume":"77","author":"Robson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0051","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/rheumatology\/kead199","article-title":"Association of the AAV-PRO questionnaire with established outcome measures in AAV","volume":"63","author":"Maunz","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0052","doi-asserted-by":"crossref","first-page":"rkae090","DOI":"10.1093\/rap\/rkae090","article-title":"Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)","volume":"8","author":"Uchida","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102708","article-title":"Comorbidities and health-related quality of life in patients with antineutrophil cytoplasmic antibody (ANCA) \u2014associated vasculitis","volume":"20","author":"Mercuzot","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0054","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.ard.2025.11.024_bib0056","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1093\/rheumatology\/keae379","article-title":"Granulomatosis with polyangiitis with and without antineutrophil cytoplasmic antibodies: a case-control study","volume":"63","author":"Casal Moura","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.11.024_bib0057","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.11.024_bib0058","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.42843","article-title":"Risk of relapse of antineutrophil cytoplasmic antibody-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids","volume":"76","author":"Junek","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0059","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00296-022-05192-3","article-title":"Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis","volume":"43","author":"Mehta","year":"2023","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-022-02796-9","article-title":"Increased frequency of IgD-CD27hiCD38hi B cells and its association with the renal involvement in ANCA-associated vasculitis","volume":"24","author":"Wang","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0061","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.38916","article-title":"Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"67","author":"Unizony","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.024_bib0062","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0063","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0064","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40620-017-0445-3","article-title":"Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome","volume":"31","author":"Crnogorac","year":"2018","journal-title":"J Nephrol"},{"issue":"9","key":"10.1016\/j.ard.2025.11.024_bib0066","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2015050511","article-title":"Urinary soluble CD163 in active renal vasculitis","volume":"27","author":"O\u2019Reilly","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.11.024_bib0067","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6861257","article-title":"Monocyte chemoattractant protein-1 in antineutrophil cytoplasmic autoantibody-associated vasculitis: biomarker potential and association with polymorphisms in the MCP-1 and the CC chemokine receptor-2 gene","volume":"2018","author":"J\u00f6nsson","year":"2018","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0068","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfy300","article-title":"Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"35","author":"Moran","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0069","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1681\/ASN.0000000000000311","article-title":"Urinary CD4 + T cells predict renal relapse in ANCA-associated vasculitis","volume":"35","author":"Prskalo","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.11.024_bib0070","article-title":"Do relapses follow ANCA rises? A systematic review and meta-analysis on the value of serial ANCA level evaluation","volume":"9","author":"Al-Soudi","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10.1016\/j.ard.2025.11.024_bib0071","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0072","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0073","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0076","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0077","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0078","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0079","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0080","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ekir.2025.04.030","article-title":"Combination cyclophosphamide and rituximab to minimize glucocorticoid use in antineutrophil cytoplasm antibody-associated vasculitis","volume":"10","author":"Salehi","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0081","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.11.024_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.ard.2025.11.024_bib0083","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","article-title":"Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis: a randomized controlled trial","volume":"178","author":"Terrier","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.11.024_bib0084","unstructured":"Long-term efficacy of remission-induction regimens for eosinophilic granulomatosis with polyangiitis\u2014ACR Meeting Abstracts [Internet]. [cited 2025 May 15]. Available from: https:\/\/acrabstracts.org\/abstract\/long-term-efficacy-of-remission-induction-regimens-for-eosinophilic-granulomatosis-with-polyangiitis\/?utm_source=chatgpt.com"},{"issue":"9","key":"10.1016\/j.ard.2025.11.024_bib0085","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ard.2025.11.024_bib0086","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0087","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","article-title":"Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Patel","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"20","key":"10.1016\/j.ard.2025.11.024_bib0088","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0089","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/acr2.11571","article-title":"Clinical benefit of mepolizumab in eosinophilic granulomatosis with polyangiitis for patients with and without a vasculitic phenotype","volume":"5","author":"Terrier","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"10.1016\/j.ard.2025.11.024_bib0090","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ard.2025.06.2131","article-title":"Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis","volume":"84","author":"Merkel","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.11.024_bib0091","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0092","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083277","article-title":"Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas","volume":"14","author":"McGovern","year":"2024","journal-title":"BMJ Open"},{"issue":"15","key":"10.1016\/j.ard.2025.11.024_bib0093","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0094","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.ekir.2025.01.022","article-title":"Obinutuzumab in rituximab-intolerant antineutrophil cytoplasmic antibody-associated vasculitis patients","volume":"10","author":"van Leeuwen","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ard.2025.11.024_bib0095","article-title":"Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ard.2025.11.024_bib0096","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0097","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13063-023-07218-y","article-title":"A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol","volume":"24","author":"McClure","year":"2023","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0098","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/cei\/uxad024","article-title":"Features of BAFF and APRIL receptors on circulating B cells in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"213","author":"Shimojima","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0099","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.42462","article-title":"Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases","volume":"75","author":"Evans","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"7774","key":"10.1016\/j.ard.2025.11.024_bib0100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0101","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0102","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.ard.2025.04.029","article-title":"Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis","volume":"84","author":"Uhlmann","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.11.024_bib0103","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.11.024_bib0104","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0105","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.11.024_bib0106","doi-asserted-by":"crossref","DOI":"10.1002\/art.43272","article-title":"A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, nonsevere, granulomatosis with polyangiitis","author":"Langford","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0107","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-024-52525-w","article-title":"Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis","volume":"15","author":"Engesser","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0108","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/ndt\/gfp783","article-title":"Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis","volume":"25","author":"Nogueira","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13075-022-02761-6","article-title":"Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)","volume":"24","author":"Gopaluni","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"24","key":"10.1016\/j.ard.2025.11.024_bib0110","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ard.2025.11.024_bib0111","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/13543784.2024.2361065","article-title":"Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study","volume":"33","author":"Yang","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"10.1016\/j.ard.2025.11.024_bib0112","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0113","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0114","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1038\/s41467-024-50747-6","article-title":"Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders","volume":"15","author":"Nishibata","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0115","first-page":"240","article-title":"Exploring the critical role of tight junction proteins in kidney disease pathogenesis","volume":"149","author":"Jayne","year":"2025","journal-title":"Nephron"},{"issue":"11S","key":"10.1016\/j.ard.2025.11.024_bib0116","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.20233411S1238c","article-title":"Claudin-1 is a therapeutic target for crescentic glomerulonephritis: TH-PO531","volume":"34","author":"Teixeira","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ard.2025.11.024_bib0117","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2021111460","article-title":"Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study","volume":"33","author":"Uhlin","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2025.11.024_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.07.001","article-title":"The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"105","author":"Berti","year":"2019","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.ard.2025.11.024_bib0119","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s10067-017-3752-0","article-title":"Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review","volume":"36","author":"Sakai","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.11.024_bib0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3899\/jrheum.221219","article-title":"Response to treatment with tofacitinib in 11 patients with refractory granulomatosis with polyangiitis","volume":"50","author":"Linde","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.11.024_bib0121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.11.024_bib0122","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ard.2025.11.024_bib0123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454747","article-title":"Cutting-edge approaches to B-cell depletion in autoimmune diseases","volume":"15","author":"Robinson","year":"2024","journal-title":"Front Immunol"},{"issue":"supplement_1","key":"10.1016\/j.ard.2025.11.024_bib0124","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/rheumatology\/keae518","article-title":"Emerging cell therapies in the vasculitis field","volume":"64","author":"Free","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:21:02Z","timestamp":1780820462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725045911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003496725045911"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.024","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}